FDA Approves JENTADUETO — Boehringer Ingelheim Pharmaceuticals, Inc.

On January 30, 2012, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for JENTADUETO (linagliptin and metformin hydrochloride) oral tablets, combining the DPP-4 inhibitor linagliptin with an enhanced-release metformin formulation. This strategic launch bolstered Boehringer Ingelheim’s presence in the growing diabetes market by offering a differentiated, non-sodium-glucose co-transporter-2 (SGLT2)-inhibitor free option aimed at addressing treatment gaps in type 2 diabetes management.